Biopharmaceutical firm Cytogen announced the results of a study that evaluated the use of its nonopioid therapeutic pain medication alone and in conjunction with chemotherapy for the treatment of prostate, breast, lung, and other cancers. The research was presented this week at the Society of Nuclear Medicine (SNM) meeting in Toronto.
Conducted at the University of Miami, the study used Quadramet (samarium lexidronam injection) as a tumoricidal agent. The authors reported that up to 93% of patients across treatment groups experienced either complete or partial relief of pain with a single dose of Quadramet. Those who received combination therapy also experienced significant improvements on bone scan, according to the Princeton, NJ-based company.
By AuntMinnie.com staff writers
June 21, 2005
Related Reading
Cytogen revenues up in Q1, but loss widens, May 5, 2005
Cytogen unveils new oncology program, April 4, 2005
Cytogen hires medical affairs VP, December 13, 2004
Advanced Magnetics, Cytogen get FDA nod, October 20, 2004
Cytogen notches record revenues, August 6, 2004
Copyright © 2005 AuntMinnie.com
